Advanced Filters
noise

retina Clinical Trials

A listing of retina medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 339 clinical trials
T Toke Bek, MD PhD Prof

TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)

TENecteplase in Central Retinal Artery Occlusion (TenCRAOS): A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization). A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + …

18 - 100 years of age Both Phase 3
T Tang Xixiang, master

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Diabetic retinopathy (DR) is an important cause of blindness.

30 - 65 years of age Both Phase N/A
A Albert O. Edwards, MD, PhD

Fenofibrate for Prevention of DR Worsening

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the …

18 - 80 years of age Both Phase 3
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Background The retina is a thin layer of tissue at the back of the eye. Retinal disease usually reduces a person s mobility because it affects how he or she moves through familiar and unfamiliar environments. Researchers want to see if a virtual reality (VR) tool can provide an easier …

5 - 100 years of age Both Phase 1
T Thomas Schwitzer, puph

Study of Bipolar Disorders and Retinal Electrophysiological Markers

The BIMAR study aims to compare electrophysiological data measured with electroretinogram (ERG) and electroencephalogram (EEG) between a group of euthymic patients with bipolar disorder (BD) and a group of healthy controls subjects. Secondarily, the investigators also want to: Compare combined electrophysiological measurements with ERG and EEG between the two groups. …

18 - 100 years of age Both Phase N/A
S Sirimon Reutrakul, MD

Circadian Amplification in Diabetic Retinopathy

This study will test the effects of a 6-week comprehensive circadian optimization intervention Amplify-RHYTHM in patients with diabetic retinopathy. The outcomes of interest are objective and subjective sleep parameters, evening salivary cortisol and melatonin levels, and glucose parameters from continuous glucose monitoring

40 - 65 years of age Both Phase N/A
B Brittany Assanah, MD

Patient Navigator Intervention for Diabetic Retinopathy

This is a pilot study of a patient navigator intervention for people living with diabetes and at high risk of diabetic blindness. The investigators are assessing the feasibility and acceptability of the intervention in preparation for a clinical trial.

18 - 100 years of age Both Phase N/A
E Eric Souied, PH

Effect of OMEGA3 Supplementation in Diabetic Retinopathy

The main objective of this study is to evaluate the efficacy at 6 months of omega 3 supplementation on macular capillary density measured in optical coherence tomography angiography in patients with minimal or moderate non proliferative diabetic retinopathy.

18 - 100 years of age Both Phase N/A

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

The central hypothesis is that inflammation mediators are biomarkers of both systemic diabetes and Diabetic Retinopathy (DR) progression in the aqueous and that sustained topical ketorolac application reduces/suppresses those inflammatory mediators thereby reducing the progression of Diabetic Retinopathy.

18 - 100 years of age Both Phase 1
A Andrew Melie

A Study of PER-001 in Participants With Diabetic Retinopathy

This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.

18 - 100 years of age Both Phase 2

Rewrite in simple language using AI